ARVN241220P35000
- 0.00
- 0.000.00%
Arvinas Newsroom
Press Release: Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $88
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Positive Outlook for Arvinas Due to Promising Safety Data and Upcoming Developments
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
Arvinas Holding's VERITAC-2 Trial Progress Drives Buy Rating Despite Adjusted Price Target
Unveiling 4 Analyst Insights On Arvinas
Arvinas Is Maintained at Outperform by BMO Capital
Arvinas Price Target Cut to $88.00/Share From $90.00 by BMO Capital
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $88
Express News | Arvinas Inc : Leerink Partners Cuts Target Price to $62 From $64
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode
Pfizer, Arvinas Delay Late-stage Trial for Breast Cancer Therapy
Express News | Arvinas Inc - Veritac-2 Trial Completion Date Moved to January 2025
Stephens Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $55
Stephens & Co. Initiates Coverage On Arvinas With Overweight Rating, Announces Price Target of $55
What You Can Learn From Arvinas, Inc.'s (NASDAQ:ARVN) P/S
Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), 2seventy Bio (TSVT)
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $48
Arvinas to Participate in Upcoming Investor Conferences